期刊文献+

新型TRK激酶小分子抑制剂的筛选与验证

Screening and Verification of Small Molecular Inhibitors against Tropomyosin-Related Kinases(TRKs)
下载PDF
导出
摘要 原肌球蛋白相关激酶(Tropomyosin-Related Kinase,TRK)属于受体酪氨酸激酶家族,具有调节细胞增殖、分化、凋亡、代谢等作用.在多种肿瘤细胞中发现TRK激酶编码基因NTRK的融合现象,TRK蛋白过表达或激酶活性组成性激活促进了肿瘤的发生发展.以TRK激酶为靶标的小分子抑制剂正处于研发之中,如Entrectinib等.本研究以Entrectinib为阳性对照,从小分子化合物库中筛选得到Crizotinib、LY2874455等7个新颖的TRK激酶小分子抑制剂,结构计算提示Dovitinib等4个化合物均属于ATP竞争性抑制剂.在NTRK1基因融合的KM12细胞体外增殖实验中,全部的TRK激酶抑制剂均能抑制细胞增殖,且LY2874455最为显著.在细胞的联合用药实验中,发现Crizotinib与Entrectinib的联用具有协同作用. Tropomyosin-related kinases (TRKs) are a group of receptor tyrosine kinases, which regulate many cellular functions including cell proliferation, cell differentiation, metabolism and apoptosis. Gene fusion of neurotropic tropomyosin receptor kinase genes ( NTRK ) coding for TRKs contributes to constitutive activation or overexpression of TRKs, which increase the risk of tumor genesis. Up to now, a variety of TRK inhibitors including Entrectinib are under research and development. In this study, 7 novel inhibitors against TRKs including Crizotinib, LY2874455 are obtained from a HTRF assay, with Entrectinib as a positive control. Structure calculation demonstrates that Dovitinib and other 3 compounds are ATP competitive inhibitors. All the novel TRK inhibitors show strong suppressive effect on cell proliferative in the colorectal carcinoma cell line KM12 with NTRK1 gene fusion, with LY287445 as the most significant among them. Furthermore, the combination of Crizotinib and Entrectinib was demonstrated to have a synergistic effect on KM12 cell proliferation.
作者 王田 吴燕华 WANG Tian;WU Yanhua(School of Life Sciences, Fudan University, Shanghai 200438, China;Biology Department, WuXi App Tec (Shanghai)Co., Ltd. Shanghai 200131, China)
出处 《复旦学报(自然科学版)》 CAS CSCD 北大核心 2019年第2期176-182,共7页 Journal of Fudan University:Natural Science
基金 国家自然科学基金青年科学基金(31000558) 上海市教委"晨光"计划(2012年)
关键词 原肌球蛋白相关激酶 小分子抑制剂 ATP竞争性抑制剂 细胞增殖 联合用药 tropomyosin-related kinases (TRKs) small molecule inhibitor ATP competitive inhibitor cell proliferation drug combination
  • 相关文献

参考文献1

二级参考文献43

  • 1Manning G,Whyte DB,Martinez R,et al.The proteinkinase complement of the human genome.Science,2002,298:1912-1934.
  • 2Dancey J,Sausville EA.Issues and progress with proteinkinase inhibitors for cancer treatment.Nat Rev Drug Dis-cov,2003,2:296-313.
  • 3Garber K,Arbor A.The second wave in kinase cancerdrugs.Nat Biotechnol,2006,24:127-130.
  • 4Noble NE,Endicott JA,Johnson LN.Protein kinaseinhibitors:insights into drug design from structure.Sci-ence,2004,303:1800-1805.
  • 5Fabbro D,Cowan-Jacob SW,Mobitz H,et al.Targetingcancer with small-molecular-weight kinase inhibitors.Methods Mol Biol,2012,795:1-34.
  • 6Card A,Caldwell C,Min H,et al.High-throughput bio-chemical kinase selectivity assays:panel developmentand screening applications.J Biomol Screen,2009,14:31-42.
  • 7Zhang JM,Yang PL,Gray NS,et al.Targeting cancerwith small molecule kinase inhibitors.Nat Rev Cancer,2009,9:28-39.
  • 8Knapp S,Sundstrom M.Recently targeted kinases andtheir inhibitors-the path to clinical trials.Curr Opin Phar-macol,2014,17:58-63.
  • 9Ma HC,Deacon S,Horiuchi K.The challenge of select-ing protein kinase assays for lead discovery optimization.Expert Opin Drug Discov,2008,3:607-621.
  • 10Yong J,Quinn CM,Kwak S,et al.Current in vitro kinaseassay technologies:the quest for a universal format.CurrDrug Discov Technol,2008,5:59-69.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部